Study to Evaluate Contraceptive Efficacy and Safety of a Progestin Only Patch in Women of Childbearing Potential
- Conditions
- Female Contraception
- Interventions
- Drug: Transdermal system containing progestin
- First Posted Date
- 2024-11-04
- Last Posted Date
- 2025-04-16
- Lead Sponsor
- Mylan Pharmaceuticals Inc
- Target Recruit Count
- 1500
- Registration Number
- NCT06672016
- Locations
- 🇺🇸
Alabama Clinical Therapeutics, LLC, Birmingham, Alabama, United States
🇺🇸SEC Clinical Research, Dothan, Alabama, United States
🇺🇸AMR Mobile, Mobile, Alabama, United States
Dose-finding Study of MR-130A-01 Contraceptive Transdermal Patch
- Conditions
- Contraception
- Interventions
- Drug: MR-130A-01 Transdermal patch
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- Mylan Pharmaceuticals Inc
- Target Recruit Count
- 168
- Registration Number
- NCT06048536
- Locations
- 🇩🇪
dinox GmbH, Berlin, Germany
Extension Study of MYL-1701P-3001 for Safety and Efficacy
- Conditions
- Diabetic Macular Edema
- Interventions
- Biological: MYL-1701P, a proposed biosimilar to Eylea
- First Posted Date
- 2020-12-19
- Last Posted Date
- 2022-08-26
- Lead Sponsor
- Mylan Pharmaceuticals Inc
- Target Recruit Count
- 52
- Registration Number
- NCT04674800
- Locations
- 🇮🇳
Mylan Investigative Site, Noida, Uttar Pradesh, India
🇮🇳Mylan Investigative site, New Delhi, India
MYL-1402O Compared With Avastin®, in Patients With Stage IV nsNSCLC
- Conditions
- NSCLC Stage IV
- Interventions
- Biological: Bevacizumab as MYL-1402OBiological: Bevacizumab as Avastin
- First Posted Date
- 2020-11-18
- Last Posted Date
- 2022-03-16
- Lead Sponsor
- Mylan Pharmaceuticals Inc
- Target Recruit Count
- 671
- Registration Number
- NCT04633564
- Locations
- 🇬🇪
LTD High Technology Medical Center University Clinic, Tbilisi, Georgia
🇵🇱Radomskie Centrum Onkologii, Radom, Poland
🇷🇺Arkhangelsk Regional Clinical Oncology Dispensary, Arkhangelsk, Russian Federation
Comparative Study to Evaluate the Efficacy and Safety of MYL-1701P and Eylea® in Subjects With Diabetic Macular Edema (DME)
- First Posted Date
- 2018-08-01
- Last Posted Date
- 2023-03-07
- Lead Sponsor
- Mylan Pharmaceuticals Inc
- Target Recruit Count
- 355
- Registration Number
- NCT03610646
- Locations
- 🇮🇳
Mylan Investigator site, Bangalore, Karnataka, India
🇷🇺Mylan Investigator Site, Saint Petersburg, Russian Federation
🇯🇵National Hospital Organization Osaka National Hospital, Osaka, Japan
Phase 1 Study of Trastuzumab Administered as a Single Intravenous Infusion
- Conditions
- Healthy
- Interventions
- Biological: Herceptin EUBiological: Herceptin USBiological: Hercules
- First Posted Date
- 2015-11-03
- Last Posted Date
- 2015-11-03
- Lead Sponsor
- Mylan Pharmaceuticals Inc
- Target Recruit Count
- 132
- Registration Number
- NCT02594761
A Comparison of Estradiol Vaginal Cream to Estrace® Cream in 350 Postmenopausal Females With Atrophic Vaginitis
- Conditions
- Atrophic Vaginitis
- Interventions
- First Posted Date
- 2014-07-21
- Last Posted Date
- 2022-03-09
- Lead Sponsor
- Mylan Pharmaceuticals Inc
- Target Recruit Count
- 366
- Registration Number
- NCT02195986
- Locations
- 🇺🇸
Physician Care Clinical Research LLC, Sarasota, Florida, United States
🇺🇸SouthCoast Research Center, Miami, Florida, United States
🇺🇸Sunrise Medical Research, Tamarac, Florida, United States
A Comparison of Mometasone Nasal Spray, Nasonex Nasal Spray, Nasonex Nasal Spray Suspension, & Placebo for Treatment of Seasonal Allergies for Safety, Efficacy, & Superiority in 1520 Male & Female Volunteers
- Conditions
- Treatment of the Signs and Symptoms of Seasonal Allergic Rhinitis
- Interventions
- Drug: Placebo Nasal Spray, 50 μL/actuation
- First Posted Date
- 2014-04-09
- Last Posted Date
- 2014-04-09
- Lead Sponsor
- Mylan Pharmaceuticals Inc
- Target Recruit Count
- 1307
- Registration Number
- NCT02109185
Fed Bioequivalence Study of Divalproex Sodium Delayed-Release Tablets, 500 mg
- Conditions
- Healthy
- Interventions
- Drug: DIVALPROEX SODIUM DELAYED-RELEASE TABLETS, USP, 500 MG
- First Posted Date
- 2010-08-18
- Last Posted Date
- 2010-08-18
- Lead Sponsor
- Mylan Pharmaceuticals Inc
- Target Recruit Count
- 20
- Registration Number
- NCT01183676
- Locations
- 🇺🇸
Kendle International Inc., Morgantown, West Virginia, United States
Bioequivalence Study of Divalproex Sodium Delayed-Release Tablets, 500 mg
- Conditions
- Healthy
- Interventions
- Drug: DIVALPROEX SODIUM DELAYED-RELEASE TABLETS, USP, 500 MG
- First Posted Date
- 2010-08-18
- Last Posted Date
- 2010-08-18
- Lead Sponsor
- Mylan Pharmaceuticals Inc
- Target Recruit Count
- 17
- Registration Number
- NCT01184391
- Locations
- 🇺🇸
Kendle International Inc., Morgantown, West Virginia, United States